Aug 26, 2024 8:30 am EDT First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
Aug 14, 2024 10:50 pm EDT Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Jun 14, 2024 11:00 am EDT LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
Jun 6, 2024 8:30 am EDT Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
Jun 3, 2024 8:30 am EDT LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
May 8, 2024 9:25 am EDT LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
